| [1] |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8):801–810.
|
| [2] |
Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8):762–774.
|
| [3] |
Cawcutt KA, Peters SG. Severe sepsis and septic shock: clinical overview and update on management[J]. Mayo Clinic proceedings, 2014, 89(11):1572–1578.
|
| [4] |
Angus DC, Vander PT. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369(9):840–851.
|
| [5] |
Vincent JL, Debacker D. Circulatory shock[J]. N Engl J Med, 2013, 369(18):1726–1734.
|
| [6] |
Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction[J]. Crit Care Med, 2007, 35(6):1599–1608.
|
| [7] |
Li L, Hu BC, Chen CQ, et al. Role of mitochondrial damage during cardiac apoptosis in septic rats[J]. Chin Med J, 2013, 126(10):1860–1866.
|
| [8] |
Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock[J]. Crit Care Clin, 2000, 16(2):251–287.
|
| [9] |
Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock[J]. Ann Intern Med, 1984, 100(4):483–490.
|
| [10] |
Pulido JN, Afessa B, Masaki M, et al. Clinical spectrum, frequency, and significance of myocardial dysfunction in severe sepsis and septic shock[J]. Mayo Clin Proc, 2012, 87(7):620–628.
|
| [11] |
Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock[J]. Eur Heart J, 2012, 33(7):895–903.
|
| [12] |
Sturgess DJ, Marwick TH, Joyce CJ, et al. Tissue doppler in critical illness: a retrospective cohort study[J]. Crit Care, 2007, 11(5):R97.
|
| [13] |
Bruni FD, Komwatana P, Soulsby ME, et al. Endotoxin and myocardial failure: role of the myofibril and venous return[J]. Am J Physiol, 1978, 235(2):H150–156.
|
| [14] |
Hinshaw LB, Archer LT, Spitzer JJ, et al. Effects of coronary hypotension and endotoxin on myocardial performance[J]. Am J Physiol, 1974, 227(5):1051–1057.
|
| [15] |
Cunnion RE, Schaer GL, Parker MM, et al. The coronary circulation in human septic shock[J]. Circulation, 1986, 73(4):637–644.
|
| [16] |
Dhainaut JF, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock[J]. Circulation, 1987, 75(3):533–541.
|
| [17] |
Hotchkiss RS, Rust RS, Dence CS, et al. Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F]fluoromisonidazole[J]. Am J Physiol, 1991, 261(4 Pt 2):R965–972.
|
| [18] |
Kumar A, Thota V, Dee L, et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum[J]. J Exp Med, 1996, 183(3):949–958.
|
| [19] |
Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock[J]. Lancet, 2004, 363(9404):203–209.
|
| [20] |
Garner LB, Willis MS, Carlson DL, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor[J]. Am J Physiol Heart Circ Physiol, 2003, 285(6):H2500–2509.
|
| [21] |
Chagnon F, Metz CN, Bucala R, et al. Endotoxin-induced myocardial dysfunction: effects of macrophage migration inhibitory factor neutralization[J]. Circ Res, 2005, 96(10):1095–1102.
|
| [22] |
Zhong J, Hwang TC, Adams HR, et al. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs[J]. Am J Physiol, 1997, 273(5 Pt 2):H2312–2324.
|
| [23] |
Tavernier B, Mebazaa A, Mateo P, et al. Phosphorylation-dependent alteration in myofilament ca2＋ sensitivity but normal mitochondrial function in septic heart[J]. Am J Respir Crit Care Med, 2001, 163(2):362–367.
|
| [24] |
Lancel S, Joulin O, Favory R, et al. Ventricular myocyte caspases are directly responsible for endotoxin-induced cardiac dysfunction[J]. Circulation, 2005, 111(20):2596–2604.
|
| [25] |
Vincent JL, Bakker J, Marécaux G, et al. Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study[J]. Chest, 1992, 101(3):810–815.
|
| [26] |
Munt B, Jue J, Gin K, et al. Diastolic filling in human severe sepsis: an echocardiographic study[J]. Crit Care Med, 1998, 26(11):1829–1833.
|
| [27] |
Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. the soluble TNF receptor sepsis study group[J]. N Engl J Med, 1996, 334(26):1697–1702.
|
| [28] |
Opal SM, Fisher CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group[J]. Crit Care Med, 1997, 25(7):1115–1124.
|
| [29] |
Landesberg G, Levin PD, Gilon D, et al. Myocardial dysfunction in severe sepsis and septic shock: no correlation with inflammatory cytokines in real-life clinical setting[J]. Chest, 2015, 148(1):93–102.
|
| [30] |
Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic[J]. JAMA, 2003, 289(2):194–202.
|
| [31] |
Hunt SA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the american college of cardiology/american heart association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the international society for heart and lung transplantation; endorsed by the heart failure society of america[J]. Circulation, 2001, 104(24):2996–3007.
|
| [32] |
Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure[J]. Circulation, 2001, 104(7):779–782.
|
| [33] |
Maurer MS, Spevack D, Burkhoff D, et al. Diastolic dysfunction: can it be diagnosed by Doppler echocardiography?[J] J Am Coll Cardiol, 2004, 44(8):1543–1549.
|
| [34] |
Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria[J]. Circulation, 2000, 101(17):2118–2121.
|
| [35] |
How to diagnose diastolic heart failure. european study group on diastolic heart failure[J]. Eur Heart J, 1998, 19(7):990–1003.
|
| [36] |
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the american college of cardiology/american heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the american college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society[J]. Circulation, 2005, 112(12):e154–235.
|
| [37] |
Mottram PM, Marwick TH. Assessment of diastolic function: what the general cardiologist needs to know[J]. Heart, 2005, 91(5):681–695.
|
| [38] |
Zakynthinos E, Kiropoulos T, Gourgoulianis K, et al. Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases[J]. Heart Lung, 2008, 37(4):275–285.
|
| [39] |
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J]. N Engl J Med, 2002, 347(3):161–167.
|
| [40] |
Grewal J, McKelvie R, Lonn E, et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction[J]. Eur J Heart Fail, 2008, 10(3):252–259.
|
| [41] |
Tschöpe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements[J]. Eur Heart J , 2005, 26(21):2277–2284.
|
| [42] |
Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis[J]. Crit Care Med, 2004, 32(3):660–665.
|
| [43] |
Januzzi JL, Morss A, Tung R, et al. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study[J]. Crit Care, 2006, 10(1):R37.
|
| [44] |
Post F, Weilemann LS, Messow CM, et al. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients[J]. Crit Care Med, 2008, 36(11):3030–3037.
|
| [45] |
McLean AS, Huang SJ, Nalos M, et al. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients[J]. Crit Care Med, 2003, 31(11):2611–2618.
|
| [46] |
He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes[J]. Hypertension, 1999, 33(1 Pt 2):283–289.
|
| [47] |
Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro[J]. Circulation, 1999, 100(10):1116–1124.
|
| [48] |
Hanford DS, Thuerauf DJ, Murray SF, et al. Brain natriuretic peptide is induced by alpha 1-adrenergic agonists as a primary response gene in cultured rat cardiac myocytes[J]. J Biol Chem, 1994, 269(42):26227–26233.
|
| [49] |
Pirracchio R, Deye N, Lukaszewicz AC, et al. Impaired plasma B-type natriuretic peptide clearance in human septic shock[J]. Crit Care Med, 2008, 36(9):2542–2546.
|
| [50] |
Heringlake M, Heide C, Bahlmann L, et al. Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers[J]. J Appl Physiol, 2004, 97(1):173–179.
|
| [51] |
Papanikolaou J, Makris D, Mpaka M, et al. New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients[J]. Crit Care, 2014, 18(3):R94.
|
| [52] |
Røsjø H, Varpula M, Hagve TA, et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome[J]. Intensive Care Med, 2011, 37(1):77–85.
|
| [53] |
Babuin L, Vasile VC, Rio PJA, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients[J]. Crit Care Med, 2008, 36(3):759–765.
|
| [54] |
Landesberg G, Vesselov Y, Einav S, et al. Myocardial ischemia, cardiac troponin, and long-term survival of high-cardiac risk critically ill intensive care unit patients[J]. Crit Care Med, 2005, 33(6):1281–1287.
|
| [55] |
Landesberg G, Jaffe AS, Gilon D, et al. Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation[J]. Crit Care Med, 2014, 42(4):790–800.
|
| [56] |
Aziz F, Tk LA, Enweluzo C, et al. Diastolic heart failure: a concise review[J]. J Clin Med Res, 2013, 5(5):327–334.
|
| [57] |
Ajayi OE, Akintomide AO, Adigun AQ, et al. Left ventricular diastolic function in nigerian patients with essential hypertension: a retrospective study to compare angiotensin converting enzyme inhibitors, calcium channel blockade or their combination[J]. Arch Drug Inf, 2008, 1(1):29–34.
|
| [58] |
Tapp RJ, Sharp A, Stanton AV, et al. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy[J]. J Am Coll Cardiol, 2010, 55(17):1875–1881.
|
| [59] |
Terpstra WF, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial[J]. J Hypertens, 2001, 19(2):303–309.
|
| [60] |
Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock[J]. Surg Gynecol Obstet, 1970, 130(6):1025–1034.
|
| [61] |
Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013, 41(2):580–637.
|
| [62] |
Piper RD, Li FY, Myers ML, et al. Effects of isoproterenol on myocardial structure and function in septic rats[J]. J Appl Physiol, 1999, 86(3):993–1001.
|
| [63] |
Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial[J]. JAMA, 2013, 310(16):1683–1691.
|
| [64] |
Hagiwara S, Iwasaka H, Maeda H, et al. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model[J]. Shock, 2009, 31(5):515–520.
|
| [65] |
Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis[J]. Surgery, 2006, 139(5):686–694.
|
| [66] |
Schmittinger CA, Dünser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression[J]. Crit Care, 2008, 12(4):R99.
|
| [67] |
Gutierrez J, Hossam A, Lazarezcu R, et al. Effect of beta blockers on sepsis outcome[J]. Med Sci Monit, 2009, 15(10):CR499–503.
|
| [68] |
Kelm DJ, Perrin JT, Cartin-Ceba R, et al. Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death[J]. Shock, 2015, 43(1):68–73.
|